Back to Search Start Over

Clinical, Immunological, and Molecular Features of Severe Combined Immune Deficiency: A Multi-Institutional Experience From India

Authors :
Prasad Taur
Manisha Madkaikar
Kirti Gupta
Madhubala Sharma
Deepti Suri
Johnson Nameirakpam
Anit Kaur
Alka Khadwal
Aparna Dalvi
Sagar Bhattad
Anjani Gummadi
Sreejesh Sreedharanunni
Michael S. Hershfield
Ranjana W. Minz
Sandip Bartakke
Tamaki Kato
Biman Saikia
Deenadayalan Munirathnam
Komal Singh
Harsha Prasada Lashkari
Fouzia Na
Amita Aggarwal
Raghuram Cp
Ramya Uppuluri
Ankit Mehta
Yu-Lung Lau
Ankita Singh
Neha Jodhawat
Surjit Singh
Revathi Raj
Stalin Ramprakash
Mukesh Desai
Yumi Ogura
Koon Wing Chan
Amit Rawat
Kaushal Sharma
Vijaya Gowri
Aruna Rajendran
Ankur Kumar Jindal
Ananthvikas Jayaram
Daniel Leung
Biju George
Rajni Kumrah
Shigeaki Nonoyama
Priyanka Kambli
Sarath Balaji
Kohsuke Imai
Pandiarajan Vignesh
Osamu Ohara
Anju Gupta
Ambreen Pandrowala
Meena Sivasankaran
Source :
Frontiers in Immunology, Frontiers in Immunology, Vol 11 (2021)
Publication Year :
2021
Publisher :
Frontiers Media SA, 2021.

Abstract

BackgroundSevere Combined Immune Deficiency (SCID) is an inherited defect in lymphocyte development and function that results in life-threatening opportunistic infections in early infancy. Data on SCID from developing countries are scarce.ObjectiveTo describe clinical and laboratory features of SCID diagnosed at immunology centers across India.MethodsA detailed case proforma in an Excel format was prepared by one of the authors (PV) and was sent to centers in India that care for patients with primary immunodeficiency diseases. We collated clinical, laboratory, and molecular details of patients with clinical profile suggestive of SCID and their outcomes. Twelve (12) centers provided necessary details which were then compiled and analyzed. Diagnosis of SCID/combined immune deficiency (CID) was based on 2018 European Society for Immunodeficiencies working definition for SCID.ResultsWe obtained data on 277 children; 254 were categorized as SCID and 23 as CID. Male-female ratio was 196:81. Median (inter-quartile range) age of onset of clinical symptoms and diagnosis was 2.5 months (1, 5) and 5 months (3.5, 8), respectively. Molecular diagnosis was obtained in 162 patients - IL2RG (36), RAG1 (26), ADA (19), RAG2 (17), JAK3 (15), DCLRE1C (13), IL7RA (9), PNP (3), RFXAP (3), CIITA (2), RFXANK (2), NHEJ1 (2), CD3E (2), CD3D (2), RFX5 (2), ZAP70 (2), STK4 (1), CORO1A (1), STIM1 (1), PRKDC (1), AK2 (1), DOCK2 (1), and SP100 (1). Only 23 children (8.3%) received hematopoietic stem cell transplantation (HSCT). Of these, 11 are doing well post-HSCT. Mortality was recorded in 210 children (75.8%).ConclusionWe document an exponential rise in number of cases diagnosed to have SCID over the last 10 years, probably as a result of increasing awareness and improvement in diagnostic facilities at various centers in India. We suspect that these numbers are just the tip of the iceberg. Majority of patients with SCID in India are probably not being recognized and diagnosed at present. Newborn screening for SCID is the need of the hour. Easy access to pediatric HSCT services would ensure that these patients are offered HSCT at an early age.

Details

ISSN :
16643224
Volume :
11
Database :
OpenAIRE
Journal :
Frontiers in Immunology
Accession number :
edsair.doi.dedup.....cd10cf0f73a717b89071a4eacb347966